We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Partners to Develop and Commercialize Noninvasive Tests for Bladder Cancer

By LabMedica International staff writers
Posted on 30 Aug 2015
An agreement between a major European university medical center and a multinational biotechnology company was designed to promote commercialization and further development of a liquid biopsy test for the diagnosis of bladder cancer.

The liquid biopsy test is based on bladder cancer DNA methylation biomarkers developed by MDxHealth SA (Herstal, Belgium) and at the University Erasmus Medical Center (Rotterdam, The Netherlands). MDxHealth has now signed an exclusive worldwide biomarker license and scientific collaboration agreement with the University Erasmus Medical Center granting MDxHealth exclusive worldwide rights for the use of a number of its bladder cancer DNA methylation biomarkers for both laboratory tests as well as in vitro diagnostic (IVD) products. University Erasmus Medical Center will receive upfront and milestone payments and royalties on net sales on any commercialized products. The two organizations have also agreed to collaborate in the clinical development of this and future bladder cancer tests.

Current diagnostic tools for the detection of bladder cancer are invasive and, with a sensitivity limited to only about 70%, leave many patients at risk of having undetected cancer. The MDxHealth liquid biopsy was designed to rule-out bladder cancer in patients with hematuria (blood in urine) noninvasively. It is based on DNA biomarkers that become modified by cancer cells. The liquid biopsy identifies these modifications at the genetic level providing the physicians with a tool to aid in the diagnosis of cancer, assess the risk of recurrence or metastasis of the cancer, and predict an individual patient’s likely response to cancer treatment.

Preliminary data from clinical trials conducted by the partners is due to be reported at the September 9–11, 2015, 11th World Congress on Urological Research that will be held in Nijmegen (The Netherlands). A cohort of 154 patients with hematuria, were tested, and it was found that the liquid biopsy urine test for bladder cancer had a negative predictive value (NPV) of 98.3%.

Dr. Jan Groen, CEO of MDxHealth, said, "Critical to our strategy is the discovery and development of noninvasive tests for urological disease. These positive data lead us to be confident that we could launch a urine based, “liquid biopsy” testing solution that will provide physicians a cost-effective, patient-friendly test to accurately aid bladder cancer detection and recurrence monitoring. We are delighted to be working alongside University Erasmus Medical Center and look forward to initiating a larger evaluation study in bladder cancer patients in due course.”

Dr. Ellen Zwarthoff, a professor at University Erasmus Medical Center, said, “Bladder cancer is the fifth most common cancer in the western world, and will continue to cost many lives unless we identify new approaches to diagnose it early, at its most treatable stages.”

Related Links:

MDxHealth SA
University Erasmus Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Automatic Hematology Analyzer
CF9600

Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more